Neovascular age-related macular degeneration (nAMD), also known as wet age‐related macular degeneration (wet AMD), is a chronic eye disease characterised by the formation and proliferation of blood vessels underneath the retina (a layer of tissue in the back of the eye that senses light and sends images to the brain). nAMD is a leading cause of central sight loss and blindness.
Ranibizumab biosimilar is a type of antibody that is targeted against a particular protein and administered via injection into the eye (intravitreal injection). Ranibizumab biosimilar has been designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula (the central part of the retina). By blocking VEGF-A, ranibizumab biosimilar would reduce the growth of the blood vessels and control leakage and swelling.
Betula verrucosa is in clinical development for the treatment of adults with confirmed tree pollen allergy-induced moderate to severe rhinoconjunctivitis. Allergic rhinoconjunctivitis is an allergic disorder of the nose and resulting in a chronic, mostly eosinophilic, inflammation of the nasal mucosa and conjunctiva. When the conjunctiva is also involved, the term rhinoconjunctivitis is more accurate. …